All In Biotech

Free tool

FAERS Monitor: Dobutamine Hydrochloride In Dextrose 5% In Plastic Container

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020201 or its brand name (Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Dobutamine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

4

Serious

1

25% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthenia1
  • blood pressure increased1
  • burkholderia test positive1
  • device issue1
  • dizziness1
  • drug monitoring procedure not performed1
  • drug therapeutic incompatibility1
  • heart rate increased1
  • product deposit1
  • product packaging confusion1
  • wrong product stored1

Reports by year received

View as table
YearReports
20201
20223

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
burkholderia test positive142793.07766.310,611
drug therapeutic incompatibility134402.26254.78,544
wrong product stored118599.13393.04,632
product deposit13378.4618.3843
drug monitoring procedure not performed12929.1536.1731
product packaging confusion12167.0396.7541
device issue158.610.714
heart rate increased153.19.712
blood pressure increased134.46.38
asthenia114.02.63
dizziness110.51.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.